SCHEMBL22323975

SCHEMBL22323975

COCOc1cc2c(=O)n(CC(F)(F)F)cnc2cc1Br

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.44
DDR1 Q08345 8/20 0.41
TNF P01375 3/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
MCL1 Q07820 1/20 0.35
LMNA P02545 1/20 0.33
NFE2L2 Q16236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447081 1.00 HDAC6 (0.44) HDAC6DDR1TNFHDAC3HDAC4
SCHEMBL22323928 0.84 HDAC6 (0.45) HDAC6DDR1TNFHDAC3HDAC4
SCHEMBL29447051 0.80 KDM4E (0.42) HDAC6TNFHDAC3HDAC4HDAC1
SCHEMBL22323965 0.80 KDM4E (0.42) HDAC6TNFHDAC3HDAC4HDAC1
SCHEMBL22323588 0.79 HDAC6 (0.38) HDAC6DDR1TNFHDAC3HDAC4
SCHEMBL29447100 0.78 TNF (0.41) HDAC6DDR1TNFHDAC3HDAC4
SCHEMBL22323772 0.78 TNF (0.41) HDAC6DDR1TNFHDAC3HDAC4
SCHEMBL4781320 0.75 HDAC6 (0.55) HDAC6TNFHDAC3HDAC4HDAC1
SCHEMBL22101746 0.72 LMNA (0.45) HDAC6DDR1HDAC3HDAC4HDAC1
SCHEMBL12933333 0.70 HDAC6 (0.65) HDAC6TNFHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 HDAC6 1838/4885DDR1 2610/4885TNF 4612/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 HDAC6 1714/4885DDR1 1849/4885TNF 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.